$LAB

LAB crypto falls 13% despite dip buying – Can bulls defend $0.12?

Lab (LAB) fell more than 13% in 24 hours, extending a downtrend, with daily volume up 335% to about $50M and a volume-to-market-cap ratio near 81%, according to the article. It cites technical rejection around $0.15, rising open interest above $124M, exchange hot-wallet selling (KuCoin), and protocol daily revenue dropping from about $191K to about $6.2K.

Original reporting
Published Aug 6, 2026, 1:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 2:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
LAB crypto falls 13% despite dip buying – Can bulls defend $0.12? — source image
Decision brief

The 30-second read

$LABBearishMed
01

Why it matters

The article links the selloff to technical rejection, rising open interest consistent with short selling, CVD showing distribution, exchange hot-wallet selling, and a sharp drop in reported daily protocol revenue, plus liquidation of longs.

02

Market read

Traders get a near-term trading read on LAB: breakdown below a key range level, derivatives positioning turning bearish, and exchange outflows coinciding with a revenue collapse narrative.

03

What to watch

The piece is heavily technical and on-chain/derivatives focused; it does not confirm whether the reported exchange outflows translate into sustained spot selling versus hedging or transfers.

Relevance 6/10Novelty 5/10Timing: at press time, during the last 24 hours selloff

Background

LAB has been trading in a mid-July range between $0.1264 and $0.1726 before breaking down below the $0.15 midpoint.

Company-level read

Ticker impact

$LABBearishMedium confidence
Context

LAB is down more than 13% as selling pressure spikes, with rising open interest and CVD showing token distribution near $0.1270 support.

Expected impact

Near-term downside risk remains elevated unless $0.1270 support stabilizes; otherwise, further liquidation-driven selling is likely.

Evidence & confidence

The article cites a breakdown below the $0.15 range mid-level, rising open interest during the drop, CVD distribution, KuCoin hot-wallet selling, and long liquidations, offset by a higher long/short ratio on Binance and OKX.

Market effects

Highlights typical altcoin microstructure risk: exchange hot-wallet outflows, revenue collapse narrative, and derivatives positioning amplifying moves.

None specified.

None specified.

Counterpoint

The long/short ratios (3.50 Binance, 10 OKX) suggest some traders are buying the dip, which can fuel a fast mean-reversion bounce if liquidation pressure eases.

Key entities

  • LAB

    The token experiencing a 13%+ drop, with derivatives and on-chain indicators pointing to heavy selling and short positioning.

  • KuCoin

    Reportedly selling LAB tokens from hot wallets, with transfers to Bitget and Gate.

  • Binance

    Reportedly showing long/short ratio changes and receiving tokens via proxy wallets; also cited for liquidation/positioning context.

  • OKX

    Reportedly showing a high long/short ratio (10), implying dip-buying interest.

Related articles

$LABMed

ARCHIMED Life Science Tools & Services Completes Acquisition of Standard BioTools’ Microfluidics Business, Now Biomark Scientific

STANDARD BIOTOOLS INC. (LAB) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 ARCHIMED Life Science Tools & Services Completes Acquisition of Standard BioTools’ Microfluidics Business, Now Biomark Scientific Business will operate as Biomark Scientific, a leader in accessible, scalable and automated genomic workflows powered by proprietary micr

$LABMed

Standard BioTools Reports Second Quarter 2026 Financial Results

STANDARD BIOTOOLS INC. (LAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Standard BioTools Reports Second Quarter 2026 Financial Results BOSTON, Mass., August 5, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended June 30, 2026. Recent